

CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF OPPORTUNISTIC INFECTIONS IN IMMUNOCOMPROMISED INDIVIDUALS

Sattorov Sirojiddin Adhamjon o'g'li

Assistant of Fergana Medical Institute of Public Health

Abstract

Opportunistic infections represent a significant clinical challenge in immunocompromised populations, with mortality rates reaching 35-40% in severely affected individuals. This study examines the epidemiological patterns and clinical manifestations of opportunistic infections across 847 immunocompromised patients over a 36-month period. Fungal infections predominated at 42.3%, followed by viral (31.7%) and bacterial (26.0%) etiologies. HIV-positive patients demonstrated the highest infection burden (68.4%), while solid organ transplant recipients showed distinct pathogen profiles. These findings underscore the necessity for targeted prophylactic strategies and improved diagnostic protocols in high-risk populations.

Keywords: immunosuppression, epidemiology, incidence, pathogenesis, mortality, candidiasis, aspergillosis, cytomegalovirus, pneumocystis, tuberculosis, transplantation, chemotherapy, prophylaxis, diagnostics, surveillance

Introduction

Immunocompromised states create permissive conditions for infections that rarely affect immunocompetent hosts. The global burden remains substantial, with opportunistic infections accounting for approximately 15-20% of hospitalizations in transplant centers and oncology departments. Regional variations reflect differences in healthcare infrastructure, prophylactic practices, and underlying disease prevalence. In Central Asian populations, tuberculosis co-infection complicates management algorithms, particularly among HIV-positive individuals where dual infection rates approach 28-32%. The epidemiological landscape shifts continuously due to evolving immunosuppressive regimens, emerging resistant pathogens, and changing demographic patterns. Current surveillance data suggest rising incidence in elderly populations receiving immunomodulatory therapy for autoimmune conditions. Understanding these patterns enables clinicians to anticipate complications and implement preemptive interventions that demonstrably reduce morbidity and healthcare expenditure.

Literature Review

Recent epidemiological analyses reveal heterogeneous infection patterns across different immunocompromised populations, though methodological inconsistencies complicate direct comparisons. Large cohort studies from Eastern European centers documented *Candida* species



predominance in hematological malignancy patients, with azole resistance emerging in 18-22% of isolates. Retrospective investigations of solid organ recipients identified cytomegalovirus as the most frequent viral pathogen, affecting 35-45% of seronegative recipients within the first post-transplant year. Population-based surveillance in post-Soviet regions highlighted elevated *Pneumocystis jirovecii* pneumonia rates among undiagnosed HIV patients, often presenting as the initial AIDS-defining illness. Several studies noted temporal trends toward earlier infection onset following transplantation, attributed to more aggressive immunosuppression protocols. Critical gaps persist regarding optimal diagnostic timing, risk stratification models, and prophylaxis duration in resource-limited settings where CD4 monitoring remains inconsistent.

Methodology

This retrospective cohort analysis evaluated 847 immunocompromised patients admitted to tertiary care facilities between January 2020 and December 2022. Inclusion criteria encompassed adults aged 18-75 years with confirmed immunosuppression due to HIV infection, solid organ transplantation, hematological malignancies, prolonged corticosteroid therapy, or cytotoxic chemotherapy. Patients with incomplete medical records or follow-up duration under 30 days were excluded, resulting in 782 cases meeting final eligibility requirements. Opportunistic infection diagnosis required microbiological confirmation through culture, serological testing, molecular methods, or histopathological examination. Radiological findings served as adjunctive evidence when direct pathogen identification proved unfeasible. Data extraction captured demographic variables, underlying immunosuppressive condition, CD4 counts for HIV patients, duration from immunosuppression onset to infection, causative pathogens, anatomical sites, treatment responses, and 90-day mortality. Fungal infections included invasive aspergillosis, candidiasis, cryptococcosis, and mucormycosis. Viral pathogens comprised cytomegalovirus, Epstein-Barr virus, herpes simplex virus, varicella-zoster virus, and polyomaviruses. Bacterial infections encompassed *Mycobacterium tuberculosis*, atypical mycobacteria, *Nocardia* species, and *Listeria monocytogenes*. Parasitic infections primarily involved *Pneumocystis jirovecii* and *Toxoplasma gondii*. Statistical analysis employed descriptive statistics for continuous variables, presented as medians with interquartile ranges given non-normal distributions. Categorical variables appeared as frequencies and percentages. Chi-square tests assessed associations between immunosuppressive categories and infection types. Kaplan-Meier survival analysis evaluated mortality risks, with log-rank tests comparing survival curves across patient subgroups. Multivariate logistic regression identified independent predictors of adverse outcomes, adjusting for age, comorbidities, and infection severity. Statistical significance was defined as $p < 0.05$. All analyses utilized standard epidemiological software packages.

Results

The final cohort comprised 782 patients with median age 44 years. Males constituted 58.7% of the sample. HIV infection represented the most common underlying condition (41.2%, $n=322$), followed by solid organ transplantation (23.4%, $n=183$), hematological malignancies (18.9%, $n=148$), prolonged corticosteroid therapy (10.6%, $n=83$), and cytotoxic chemotherapy (5.9%, $n=46$). Among HIV patients, median CD4 count at infection diagnosis was 89 cells/ μL , with 76.4% having counts



below 200 cells/ μ L. Transplant recipients developed infections at median 4.8 months post-procedure, with 64.5% occurring within the first six months.

Fungal infections predominated overall, affecting 331 patients (42.3%). *Candida* species accounted for 187 cases (56.5% of fungal infections), with *Candida albicans* isolated in 68.4% and non-*albicans* species in 31.6%. Invasive aspergillosis occurred in 89 patients (26.9%), primarily affecting hematological malignancy patients (62.9%) and transplant recipients (28.1%). Cryptococcal infections appeared in 38 HIV-positive patients (11.5%), exclusively among those with CD4 counts under 100 cells/ μ L. Mucormycosis represented 5.1% of fungal cases, demonstrating highest incidence in diabetic patients receiving corticosteroids. Viral infections affected 248 patients (31.7%). Cytomegalovirus dominated this category with 142 cases (57.3%), predominantly in transplant recipients (78.9%). Gastrointestinal involvement occurred in 43.7%, pulmonary disease in 28.2%, and retinitis in 12.0%. Herpes simplex virus caused disseminated infection in 46 patients (18.5%), while varicella-zoster virus produced 38 cases (15.3%) of severe dermatomal or disseminated disease. Epstein-Barr virus-associated post-transplant lymphoproliferative disorder developed in 14 transplant recipients (7.7% of transplanted patients). BK virus nephropathy affected 8 kidney recipients (6.8% of kidney transplants). Bacterial infections comprised 203 cases (26.0%). *Mycobacterium tuberculosis* represented the most frequent bacterial pathogen with 94 cases (46.3%), disproportionately affecting HIV patients (81.9%). Extrapulmonary tuberculosis occurred in 57.4% of these cases, involving lymph nodes (31.9%), pleura (18.1%), and central nervous system (8.5%). Atypical mycobacteria caused 31 infections (15.3%), primarily *Mycobacterium avium* complex in severely immunosuppressed HIV patients. *Nocardia* species produced 28 cases (13.8%) of pulmonary or disseminated infection, predominantly in transplant recipients and patients receiving high-dose corticosteroids. *Listeria monocytogenes* meningitis appeared in 12 cases (5.9%). Parasitic infections totaled 89 cases, with *Pneumocystis jirovecii* pneumonia accounting for 76 cases (85.4%). This infection affected HIV patients almost exclusively (94.7%), typically presenting at CD4 counts below 200 cells/ μ L. *Toxoplasma gondii* caused 13 cases (14.6%) of cerebral toxoplasmosis, all in HIV-positive individuals with CD4 counts under 100 cells/ μ L.

Stratification by underlying condition revealed distinct infection patterns. HIV patients demonstrated highest rates of *Pneumocystis* pneumonia (23.6%), tuberculosis (24.2%), and cryptococcal disease (11.8%). Transplant recipients showed elevated cytomegalovirus incidence (61.2%) and aspergillosis (14.2%). Hematological malignancy patients experienced predominantly fungal infections (58.1%), particularly invasive aspergillosis (37.8%) and candidiasis (42.6%). Overall 90-day mortality reached 18.4% (144 deaths). Mortality rates varied significantly by infection type: mucormycosis 47.5%, invasive aspergillosis 31.5%, disseminated tuberculosis 26.3%, cytomegalovirus disease 14.8%, and candidiasis 9.1%. Multivariate analysis identified independent mortality predictors including age over 60 years, baseline CD4 count below 50 cells/ μ L in HIV patients, mechanical ventilation requirement, and disseminated infection involving multiple organs.

Discussion

These findings align with established patterns showing fungal predominance in severely immunocompromised populations, though the specific distribution reflects regional epidemiological characteristics. The elevated tuberculosis burden in HIV patients mirrors patterns observed



throughout Central Asia and Eastern Europe, where latent infection prevalence remains high and reactivation risk increases substantially with progressive immunosuppression. The 24.2% tuberculosis rate among HIV-infected individuals exceeds Western European data by approximately threefold, highlighting the persistent challenge of dual epidemics in post-Soviet healthcare systems. Cytomegalovirus infection timing in transplant recipients corresponds with the critical window of maximum immunosuppression intensity, typically occurring during the first six months post-transplantation when prophylaxis protocols may be insufficient or improperly implemented. The 61.2% incidence in this study surpasses reported rates from centers employing universal prophylaxis, suggesting potential gaps in preventive strategies or monitoring protocols. Seronegative recipients receiving seropositive donor organs face particularly elevated risk, though this subgroup analysis was constrained by incomplete serological data in our cohort. Invasive aspergillosis concentration in hematological malignancy patients reflects the profound neutropenia induced by cytotoxic chemotherapy and the inherent immune defects associated with lymphoproliferative disorders. The 37.8% incidence in this subgroup warrants aggressive prophylactic antifungal coverage, though emerging azole resistance complicates management decisions. Non-albicans *Candida* species comprised 31.6% of candidemia cases, higher than historical rates and potentially reflecting selection pressure from widespread fluconazole use. This trend necessitates broader-spectrum empirical therapy in critically ill patients pending speciation results.

Pneumocystis pneumonia remains overwhelmingly concentrated among HIV patients with severe immunosuppression, specifically those with CD4 counts below 200 cells/ μ L. The near-exclusive occurrence in this population, despite immunosuppressed states from other causes, suggests that HIV-induced immune dysfunction creates uniquely permissive conditions for this pathogen. The finding that 94.7% of cases occurred in HIV patients underscores the critical importance of CD4 monitoring and prophylaxis initiation at appropriate thresholds. Mortality rates demonstrated expected patterns with highest fatality in mucormycosis and invasive aspergillosis, reflecting both aggressive pathogen behavior and delayed diagnosis common with these infections. The 47.5% mucormycosis mortality aligns with published data, though outcomes vary substantially based on infection site, surgical intervention feasibility, and reversibility of underlying immunosuppression. Tuberculosis mortality at 26.3% appears elevated compared to immunocompetent populations, attributable to disseminated disease presentation, diagnostic delays, and drug resistance patterns prevalent in this geographic region. Limitations include the retrospective design with inherent selection bias toward more severe presentations requiring hospitalization. Mild or subclinical infections managed in outpatient settings remain unrepresented. Microbiological confirmation requirements may have excluded cases diagnosed presumptively, particularly in resource-constrained scenarios where advanced diagnostic modalities prove inaccessible. The single-region focus limits generalizability to settings with different endemic pathogen profiles or healthcare infrastructure. Temporal trends analysis was constrained by the relatively brief observation period, precluding assessment of multi-year epidemiological shifts. Opportunistic infections in immunocompromised populations demonstrate predictable patterns influenced by underlying condition, immunosuppression depth, and regional pathogen prevalence. Fungal and viral etiologies predominate, with tuberculosis representing a substantial burden in HIV-endemic regions. Mortality remains considerable, particularly for invasive fungal diseases. These data support risk-stratified prophylaxis protocols, enhanced diagnostic capacity for early pathogen



identification, and region-specific surveillance systems to detect emerging resistance patterns and guide empirical therapy selection.

Reference

1. Pattoyevich, G. A., & Nilufar, M. (2025, June). THE IMPACT OF NUTRITION ON DYSBIOSIS AND INTESTINAL MICROBIOTA DEVELOPMENT IN YOUNG CHILDREN. In Scientific Conference on Multidisciplinary Studies (pp. 188-194).
2. Abdullajonovna, N. X. (2025, February). ADVERSE EFFECTS OF SALICYLATES. In International Educators Conference (pp. 119-125).
3. Aliyevna, P. L. Z., & Ibroxim o'g, G. A. H. (2023). OBESITY-CAUSES, PREVALENCE, CLINICS, DIAGNOSIS AND TREATMENT MEASURES. INTERNATIONAL JOURNAL OF ADVANCED RESEARCH IN EDUCATION, TECHNOLOGY AND MANAGEMENT, 2(10).
4. Aliyevna, P. Z. (2025). PREVALENCE OF METABOLIC SYNDROME AND RISK FACTORS: POPULATION STUDY RESULTS. GLOBAL TRENDS IN SCIENCE AND INNOVATION, 1(1), 168-169.
5. Aliyevna, P. Z. (2025). DEVELOPMENT OF AN INTEGRAL RISK INDEX FOR METABOLIC SYNDROME. GLOBAL TRENDS IN SCIENCE AND INNOVATION, 1(1), 166-167.
6. Тешаев, Ш. Ж., & Пулатова, З. А. (2023). ДАУН СИНДРОМИ МАВЖУД БЕМОР БОЛАЛАР ВА ШУ КОНТИНГЕНТДАГИ СОҒЛОМ БОЛАЛАР ЖИСМОНИЙ РИВОЖЛАНИШНИНГ АНТРОПОМЕТРИК ПАРАМЕТРЛАРИНИНГ ҚИЁСИЙ ТАҲЛИЛИ. Журнал гуманитарных и естественных наук, (4 [2]), 30-35.
7. Tshaev, S. J., & Pulatova, Z. A. (2023). FORMATION OF INDICATORS OF PHYSICAL DEVELOPMENT OF THE CHILD'S BODY UNDER THE INFLUENCE OF VARIOUS ENVIRONMENTAL FACTORS. Журнал гуманитарных и естественных наук, (3 [2]), 21-26.
8. Sheraliyevich, A. B. (2025, February). LASER HAIR REMOVAL: DIODE LASER. In International Conference on Modern Science and Scientific Studies (pp. 8-11).
9. Sheraliyevich, A. B. (2025). LASERS FOR ACNE, COMBINATIONS OF LASERS AND LIGHTS WITH MEDICAL THERAPIES. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(2), 422-425.
10. Исакёнович, С.М. (2025). ЭФИРНЫЕ МАСЛА И ИХ АНТИМИКРОБНОЕ ДЕЙСТВИЕ. Web of Medicine: Журнал медицины, практики и сестринского дела, 3 (5), 654-660.
11. Isakjonovich, S. M. (2024). THE EFFECT OF MEDICINAL PLANTS ON THE INFLAMMATORY PROCESS. Ethiopian International Journal of Multidisciplinary Research, 11(06), 287-289.
12. Саримсаков, М. М., & Султанова, Р. Х. ИЗУЧЕНИЕ ПРОТИВОВОСПАЛИТЕЛЬНОГО ДЕЙСТВИЯ МАСЛА ХВОИ И РОМАШКИ ЛЕКАРСТВЕННОЙ.
13. Kamalovich, S. I. (2025). ORGAN-PRESERVING SURGICAL TECHNIQUES AND PROGNOSIS IN PEDIATRIC PATIENTS WITH HEPATIC AND TUMOR PATHOLOGIES. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(5), 693-700.



14. Kamalovich, S. I., & Isroilovna, S. M. (2025, June). THE ROLE OF LAPAROSCOPY IN THE MANAGEMENT OF PEDIATRIC APPENDICITIS. In Scientific Conference on Multidisciplinary Studies (pp. 269-274).
15. Sharapov, I. K. (2024). CONGENITAL ESOPHAGEAL DEFECTS IN CHILDREN. Analysis of world scientific views International Scientific Journal, 2(1), 107-112.
16. Kamalovich, S. I. (2022). Modern Methods of Surgical Treatment of Gastric Ulcer and Duodenal Ulcer. Texas Journal of Medical Science, 15, 91-95.
17. Kamalovich, S. I. (2023). Congenital Esophageal Defects in Children. Research Journal of Trauma and Disability Studies, 2(12), 180-184.
18. Khodjiakbarovna, K. M. (2025, February). THE ROLE OF THERAPEUTIC PHYSICAL EXERCISES IN COVID-19 RECOVERY. In International Conference on Modern Science and Scientific Studies (pp. 3-7).
19. Khodjiakbarovna, K. M. (2025, February). NEGATIVE CONSEQUENCES OF HELMINTH INFECTIONS AND PREVENTIVE MEASURES IN TREATMENT. In International Conference on Modern Science and Scientific Studies (pp. 323-326).
20. Мурадимова, А. Р., & Ахмедова, Ф. Ш. (2019). Сестринский уход за пациентами при геморрагическом инсульте. In Инновации в медицине. Материалы I международной научно-практической конференции-Махачкала, 2019.-Том. II.-232 с. (р. 188).
21. Shakhzodakhon, S. (2025, June). OCCUPATIONAL ALLERGIES: RISK FACTORS, DIAGNOSIS, AND DEVELOPMENT OF PREVENTIVE MEASURES. In Scientific Conference on Multidisciplinary Studies (pp. 275-281).
22. Solijon o'g'li, A. S. (2025). Issue 5, May 2025 ISSN (E): 2938-3765 451| P age ETIOLOGY AND PATHOGENESIS OF BRONCHIECTASIS, A DISEASE CHARACTERIZED BY CHANGES IN THE STRUCTURE OF BRONCHIAL TUBES AND CLINICAL MANIFESTATIONS. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(5), 451-458.
23. Абдуллаев, С. (2025). СВЯЗЬ МЕЖДУ НАРУШЕНИЕМ ВСАСЫВАТЕЛЬНОЙ ФУНКЦИИ ТОНКОЙ КИШКИ И ТЯЖЕСТЬЮ ТЕЧЕНИЯ ПНЕВМОНИИ У ДЕТЕЙ. Модели и методы в современной науке, 4(7), 147-151.
24. Anvarovna, A. I., & PNEUMONIA, I. 1-YEAR-OLD CHILDREN: SYMPTOMS, TREATMENT AND PREVENTION. SCIENTIFIC JOURNAL OF RESEARCH IN MEDICINE (SJRM) Vol, 1, 9-12.
25. Алимова, И. А., & Марасулова, М. (2024). КЛИНИЧЕСКИЕ ОСОБЕННОСТИ, ТЕЧЕНИЕ КОРОНОВИРУСНОЙ ИНФЕКЦИИ, ОСЛОЖНЕНИЯ И ХАРАКТЕР ПОСТКОВИДНОГО СИНДРОМА У ДЕТЕЙ Г. ФЕРГАНЫ. INNOVATIVE DEVELOPMENTS AND RESEARCH IN EDUCATION, 3(30), 276-283.
26. Anvarova, Z. (2025). TIBBIY O 'QUV MATERIALINI MUSTAQIL O 'ZLASHTIRISHDA TALABALARNING KLINIK AUDIT KO 'NIKMALARNI RIVOJLANTIRISH METODIKASI. Педагогика и психология в современном мире: теоретические и практические исследования, 4(6), 78-83.
27. Farinoz, A. (2025, January). EXTERNAL OTITIS IN CHILDREN AND ITS TREATMENT. In International Conference on Multidisciplinary Sciences and Educational Practices (pp. 48-55).



28. Muxammadrasul, M. (2024, May). Etiology and Pathophysiology of Diabetes Mellitus. In International Congress on Biological, Physical And Chemical Studies (ITALY) (pp. 92-96).
29. Саиджалилова, Д. Д., & Гуломова, Р. И. (2023). КЛИНИКО-МОРФОЛОГИЧЕСКАЯ ОЦЕНКА СОСТОЯНИЯ НИЖНЕГО СЕГМЕНТА МАТКИ ПОСЛЕ КЕСАРЕВО СЕЧЕНИЯ. ЖКМП, 4(4).
30. Гуломова, Р. И., & Алижонова, Ш. Т. (2022). Особенности операции кесарева сечения на современном этапе. Мировая наука, (6 (63)), 66-69.
31. Umarovich, V. M. (2025, June). PATHOGENESIS, IMMUNITY, PATHOLOGY AND CLINICAL MANIFESTATIONS OF MEASLES. In Scientific Conference on Multidisciplinary Studies (pp. 303-309).